Cosmos Health announced that its wholly owned subsidiary, Cana Laboratories S.A., has signed a contract manufacturing agreement with Medical Pharmaquality S.A. for MYCOFAGYL® pessaries, further expanding its pipeline of pharmaceutical products.
Under the terms of the agreement, Cana will manufacture MYCOFAGYL®, a combination of Metronidazole (500mg) and Nystatin (100,000 IU) in pessary dosage form. The product will be supplied in packs of 10 units (2 PVC/PE strips x 5 pessaries). The Company anticipates manufacturing and delivering 3 million pessaries per year.
MYCOFAGYL® is widely prescribed for the treatment of vaginal infections, including bacterial vaginosis and candidiasis (yeast infections). By combining the antibacterial and antiprotozoal action of Metronidazole with the antifungal action of Nystatin, MYCOFAGYL® provides a dual-action approach that helps restore balance and effectively treat common vaginal infections such as bacterial vaginosis and candidiasis.
This agreement highlights Cana’s expertise in high-quality pharmaceutical manufacturing and expands its portfolio to include gynecology, adding to the wide range of therapeutic categories in which the company is active. By broadening its scope, Cana reinforces its position as a trusted partner to pharmaceutical companies across Europe and beyond.
Greg Siokas, CEO of Cosmos Health, stated: “We are excited to expand our order book with long-term, high-volume commitments, further reinforcing Cana’s reputation as a reliable partner in the pharmaceutical industry. This agreement reflects our partner’s confidence in Cana’s quality, expertise, and state-of-the-art facilities, while MYCOFAGYL represents another step in our strategy to diversify our product offerings. Women’s health remains a critical therapeutic area, and this agreement not only strengthens our manufacturing pipeline but also underscores the strong growth momentum of our contract manufacturing business and our ability to secure new high-margin contracts that strengthen our cash flow.”